Publication

Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.

Authors not recorded

Clin Cancer Res2009PMID 19147750stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (16)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 16

cancerLung Non-Small Cell Carcinomacivic_curation1.00
cancerMalignant Neoplasmcivic_curation1.00
drugErlotinibcivic_curation1.00
drugGefitinibcivic_curation1.00
drugMultikinase Inhibitor AEE788civic_curation1.00
geneEGFRcivic_curation1.00
variantEGFR A864Tcivic_curation1.00
variantEGFR G719Scivic_curation1.00
variantEGFR L747_P753delinsScivic_curation1.00
variantEGFR L838Vcivic_curation1.00
variantEGFR L858Rcivic_curation1.00
variantEGFR N826Scivic_curation1.00
variantEGFR R776Ccivic_curation1.00
variantEGFR S768Icivic_curation1.00
variantEGFR T790Mcivic_curation1.00
variantEGFR V742Acivic_curation1.00

Curated evidence

Evidence citing this paper (20)

civicCuratedShowing 1–20 of 20 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR A864T1
Erlotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	—	accepted	EID4495 In an in vitro study, a Ba/F3 cell line expressing EGFR A864T demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). … (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
EGFR G719S2
Erlotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	—	accepted	EID4190 In an in vitro study, a Ba/F3 cell line expressing EGFR G719S demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). … (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
Gefitinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	—	submitted	EID2617 In vitro studies showed that cells with S768I mutation had moderate sensitivity (IC50=90-315nM) to gefitinib , in comparison to the del747-753insS (IC50= 7nM) or L858R (IC50=12-20nM) mutations that co… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
EGFR L747_P753delinsS1
Erlotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	—	accepted	EID4266 In an in vitro study, a Ba/F3 cell line expressing EGFR L747_P753>S demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L8… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
EGFR N826S1
Erlotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	—	accepted	EID4496 In an in vitro study, a Ba/F3 cell line expressing EGFR N826S demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sen… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
EGFR R776C2
Erlotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	—	accepted	EID4468 In an in vitro study, a Ba/F3 cell line expressing EGFR R776C demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). … (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
Gefitinib	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Sensitivity Response	3	submitted	EID5818 EGFR R776C was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independence to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
EGFR V742A2
Erlotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	—	accepted	EID4197 In an in vitro study, a Ba/F3 cell line expressing EGFR V742A demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). … (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
Gefitinib	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Sensitivity Response	2	submitted	EID5819 EGFR V742A was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
EGFR D761N2
Erlotinib + GefitinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Sensitivity Response	2	submitted	EID5820 EGFR D716N was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
Multikinase Inhibitor AEE788	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	submitted	EID5821 EGFR D716N was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
EGFR G810S2
Erlotinib + GefitinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Sensitivity Response	2	submitted	EID5824 EGFR G810S was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independence to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
Multikinase Inhibitor AEE788	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID5825 EGFR G810S was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
EGFR L838V1
Erlotinib + GefitinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	2	accepted	EID4280 In an in vitro study, a Ba/F3 cell line expressing EGFR L838V demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sen… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
EGFR L858R1
Erlotinib + Gefitinib + Multikinase Inhibitor AEE788Substitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID3811 EGFR L858R was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
EGFR L861Q1
Erlotinib + Gefitinib + Multikinase Inhibitor AEE788Substitutes	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Sensitivity Response	2	submitted	EID5826 EGFR L861Q was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
EGFR S768I1
Erlotinib + GefitinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID4274 In an in vitro study, a Ba/F3 cell line expressing EGFR S768I demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sen… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
EGFR S784F2
Erlotinib + GefitinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Sensitivity Response	2	submitted	EID5822 EGFR S784F was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
Multikinase Inhibitor AEE788	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID5823 EGFR S784F was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
EGFR T790M1
Erlotinib + Gefitinib + Multikinase Inhibitor AEE788Substitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID3810 Experimental - EGFR T790M mutation has been associated with resistance to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In an in vitro study, Ba/F3 cells stably … (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic